INNOVADERM CRO IS NOW INDERO.
READ THE ANNOUNCEMENT
Talk to us

Dr. Robert Bissonnette, EY Entrepreneur Of The Year® 2024 finalist

Ana Palijan, PhD

Ana Palijan, PhD

Director, Early Phase and Translational Research

Author picture

We are thrilled to announce that Dr. Robert Bissonnette, the visionary founder, and CEO of Innovaderm Research, has been shortlisted for the esteemed EY Entrepreneur Of The Year® 2024 award.

Dr. Bissonnette is a world-renowned key opinion leader in psoriasis and atopic dermatitis. His entrepreneurial spirit, curiosity, creativity, and analytical thinking have led Innovaderm to become the world’s largest privately owned dermatology specialized CRO. Under his leadership, Innovaderm has been recognized by the CRO Leadership Awards for 4 consecutive years, completed 500+ dermatology clinical trials which recruited 12,000+ subjects. His company has grown from a local entity in Montreal to a global organization with 400+ employees around the world.

His commitment to dermatology research is evident in his 200+ scientific peer-reviewed publications and his past role as a founding member of the International Eczema Council and his continuous patient care. His innovative approaches have led to the improvement of non-surgical techniques in sample collection and study designs.

But the adventure does not end here! The next step in this exciting process is an interview in front of a jury. This esteemed panel will select the Entrepreneur Of The Year 2024. Dr. Bissonnette will have the opportunity to showcase his vision, leadership, and the impact Innovaderm has made in the field of dermatology.

Join us in congratulating Dr. Bissonnette on this remarkable achievement.

SHARE THIS POST

Subscribe to our newsletter.

Do not miss out on valuable insights and research updates. Join our scientific community today!

This field is for validation purposes and should be left unchanged.
Talk to us

Jeff Smith

Chef de la direction
Linkedin

Jeff Smith, Chef de la direction d’Indero Recherches, apporte près de 30 ans d’expérience dans l’industrie pharmaceutique et CRO, s’étant distingué par son leadership exceptionnel, sa vision stratégique et son innovation. L’expertise de Jeff couvre des opérations mondiales, la gestion de la croissance, ainsi que la promotion d’une culture d’entreprise collaborative. Ses atouts en matière de création de valeur, de gestion des partenaires et d’opérations CRO ont toujours contribué au succès dans ses fonctions précédentes. Sous la direction de Jeff, Indero continue d’étendre ses capacités, faisant progresser les connaissances médicales et les nouvelles thérapies en dermatologie et en rhumatologie.

Revolutionize Your Topical Trials

Efficacy insights in days, not months.

 Indero’s Early Phase 1 model enables sponsors to initiate topical studies that detect early pharmacodynamic signals much sooner than traditional phase 1, using microdosing and transcriptomic analysis. This approach reduces preclinical requirements, shortens study duration from 8–12 weeks to ≤3 days, and lowers costs, helping teams make informed go/no-go decisions faster.
LEARN MORE >